drugset / Trial / NCT07542483

A Study of Lebrikizumab in Adults With Nummular Eczema

NCT07542483

Phase 3 Not yet recruiting 270 enrolled Almirall, S.A.
RandomizedParallel-groupDouble-blindTreatment

Summary

The main aim of the study is to evaluate the efficacy, safety, and tolerability of lebrikizumab treatment in adult participants with Nummular Eczema (NE) who are not adequately controlled with Topical corticosteroids (TCS) or when this treatment is not medically advisable.

Timeline

Start
2026-04
Primary completion
2028-08
Completion
2029-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Lebrikizumab Monoclonal antibody Subcutaneous

Indications

No indication recorded.